Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT04040413
Recruiting Observational

Database Maintenance for Bariatric Procedures

NCT04040413 · tracked via the Priya Life Science Israel tracker
Sponsor
Sheba Medical Center
Phase
Observational
Started
2014-01-01
Last updated
2024-04-23

Condition(s) studied

Obesity, MorbidBariatric Surgery Candidate

Investigational drug(s) / intervention(s)

bariatric surgery

bariatric surgery: All bariatric procedures

Study summary

Bariatric surgery registry for quality control and investigational purposes.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * morbid obesity Exclusion Criteria: * unfit for surgery

Primary outcome measure(s)

  • Surgery type — 10 years
    Sleeve gastrectomy or Roux-Y gastric bypass (RYGBP) or Single anastomosis gastric bypass (SAGB) or biliopancreatic diversion (BPD/DS) or single anastomosis duodeno-ilial bypass (SADI)
  • Percent total weight loss (%TWL) — 1 year from surgery
    \[(Weight at time of surgery - Weight at time point)/Weight at time of surgery\]X100
  • Percent total weight loss (%TWL) — 5 years from surgery
    \[(Weight at time of surgery - Weight at time point)/Weight at time of surgery\]X100
  • Percent total weight loss (%TWL) — 10 years from surgery
    \[(Weight at time of surgery - Weight at time point)/Weight at time of surgery\]X100
  • Percent BMI loss (%BMIL) — 1 year from surgery
    \[BMI at time of surgery - BMI at time point)/BMI at time of surgery\] X 100
  • Percent BMI loss (%BMIL) — 5 years from surgery
    \[BMI at time of surgery - BMI at time point)/BMI at time of surgery\] X 100
  • Percent BMI loss (%BMIL) — 10 years from surgery
    \[BMI at time of surgery - BMI at time point)/BMI at time of surgery\] X 100

Trial sites (1)

FacilityCityRegionStatus
Sheba Medical Center Ramat Gan Israel Recruiting

More Sheba Medical Center trials in Israel

Clemastine Treatment in Individuals With Williams Syndrome Active, not recruiting
Hepatopulmonary Radio-sterilization With Immunotherapy Starting soon
Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery Recruiting
Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events Recruiting
Does Sexual Intercourse Affect the Outcomes of Frozen-thawed Embryo Transfer? Recruiting

Other trials for the same condition

Postoperative VR for Recovery After Bariatric Surgery Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04040413 on ClinicalTrials.gov ↗ ← All trials in Israel